Pharm Exam 4 Last Lecture (Chemotherapy)

Question 1

Bevacizumab

Answer 1

MOA: Binds VEGF-R binding
Toxicity: Bleeding, Thromboembolism

Question 2

Paclitaxel

Answer 2

MOA: Mitosis inhibitors; M phase
Toxicity: Myelosuppression, anemia

Question 3

Methotrexate

Answer 3

MOA: Antimetabolite; S phase
Toxicity: Mucositis, thrombocytopenia
Consideration: Leucovorin rescue

Question 4

Carmustine

Answer 4

MOA: Alkylate DNA
Toxicity: N/A
Consideration: Crosses BBB

Question 5

Imatinib

Answer 5

MOA: Bcr-Abl
Toxicity: Edema
Consideration: Leukemias; test for mutation

Question 6

Cisplatin

Answer 6

MOA: Alkylate DNA
Toxicity: Renal, acoustic nerve damage (THINK KORCH’S DAUGHTER)
Consideration: Give w/ amifostine (renal)

Question 7

Vinbalstine

Answer 7

MOA: Mitosis inhibitors; M phase
Toxicity: Myelosuppression

M phase have no special considerations :)

Question 8

Eroltinib

Answer 8

MOA: Blocks EGFR kinase activity
Toxicity: Rash, diarrhea, anorexia
Consideration: Test for EGFR expression and mutations

Question 9

Vinicristine

Answer 9

MOA: Mitosis inhibitors, M phase
Toxicity: Neurotoxicity

Question 10

6-Mercaptopurine

Answer 10

MOA: Antimetabolites; S phase
Toxicity: Bone marrow, jaundice, allopurinol
Consideration: Leucovorin rescue

Question 11

Cyclophosphamide

Answer 11

MOA: Alkylate DNA
Toxicity: Forms acrolein-hemorrhagic cystitis
Consideration: MENSA/hyrdration

Question 12

Bleomycin

Answer 12

MOA: G2-M phase
Toxicity: Hypersensitivity, pulmonary fibrosis
Consideration: Low myelosuppression

Question 13

5-Flurouracil

Answer 13

MOA: Antimetabolites; S phase
Toxicity: Oral, GI ulceration
Consideration: Leucovorin ENHANCES activity

Question 14

Doxorubicin

Answer 14

MOA: Alkylate DNA
Toxicity: Cardiotoxic (iron)
Consideration: Dexrazoxane (iron)

Question 15

Cetuximan

Answer 15

MOA: Antibody that binds EGFR
Toxicity: Acneiform, hypomagnesia
Consideration: Test for EGFR expression and mutations (same w/ Erlotinib)